Results of Operations and Financial Condition. On August 6, 2026, OmniAb, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Chief Operating Officer — Amechi Nwachuku: Mr. Amechi Nwachuku was appointed as the Chief Operating Officer of OmniAb, Inc.

Results of Operations and Financial Condition. On May 7, 2026, OmniAb, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

Results of Operations and Financial Condition. On March 4, 2026, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Results of Operations and Financial Condition. On November 4, 2025, OmniAb, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Unregistered Sales of Equity Securities. The disclosures set forth in

Entry into a Material Definitive Agreement. On August 24, 2025, OmniAb, Inc. (“OmniAb” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 21,254,106 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $1.40 per Share or with respect to any Purchaser that is an officer, director, empl…

Results of Operations and Financial Condition. On August 6, 2025, OmniAb, Inc. issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Results of Operations and Financial Condition. On May 8, 2025, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Director — Steven C. Crouse and Philip J. Gotwals, Ph.D.: Two new directors were appointed to the board as part of a routine annual meeting process.

Results of Operations and Financial Condition. On March 18, 2025, OmniAb Inc. (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Results of Operations and Financial Condition. On November 12, 2024, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Results of Operations and Financial Condition. On August 8, 2024, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…

Director — Joshua Tamaroff: Mr. Tamaroff resigned from the Board of Directors due to his pending departure from Avista Capital Partners.

Results of Operations and Financial Condition. On May 9, 2024, OmniAb, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Results of Operations and Financial Condition. On March 20, 2024, OmniAb Inc. (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Results of Operations and Financial Condition. On November 9, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Sec…

Director, Audit Committee Chair, Human Capital Management and Compensation Committee Member — Steven Love: Steven Love was appointed as a new Director and assumed multiple key roles on the Board.

Results of Operations and Financial Condition. On August 10, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Results of Operations and Financial Condition. On May 11, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Results of Operations and Financial Condition. On March 30, 2023, OmniAb Incorporated (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2022. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the S…

Results of Operations and Financial Condition. On January 9, 2023, OmniAb, Inc. (the “Company” or “OmniAb”) announced that its preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2022 were approximately $88 million. The preliminary unaudited cash position discussed above is subject to the completion of financial closing procedures and other developments that may arise between now and the time the financial results for the fourth quarter are finalized, as…

in this report or the presentation available on the Company’s website. The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, althou…

Other Information On November 18, 2022, OmniAb, Inc. (the “Company”) announced that Janssen Biotech, Inc. (“Janssen”) has notified the Company that the first commercial sale (as defined under the terms of the licensing agreement between OmniAb and an affiliate of Janssen) of TECVAYLI ™ (teclistamab) in the United States had occurred, and the Company now expects to receive the related $25 million milestone payment and expects to book $25 million of milestone revenue in Q4 2022. Forward-Looking…

Results of Operations and Financial Condition. On November 15, 2022, OmniAb Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022. OmniAb was part of Ligand Pharmaceuticals Incorporated until its spin-off and merger with a subsidiary of Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) as of November 1, 2022. A copy of that press release is furnished herewith as Exhibit 99.1.…